ZBTB4

Across TCGA pan-cancer cohorts, ZBTB4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZBTB4 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher ZBTB4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB4 expression acts as an unfavorable survival marker.

CHOL, BLCA, and LUAD are the cancer types where ZBTB4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.019	0.800	<.001	24	view →
BLCA	OS	Median	III,IV	0.153	0.684	.001	15	view →
LUAD	OS	Median	All	0.090	0.788	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZBTB4–CHOL (OS)

Open the CHOL breakdown →